Four named finalists for HX360 Innovation Challenge

Four companies have made the cut and will be finalists in the HX360 Innovation Challenge competition.

Selected from an original field of 83 entries, these companies will present their solutions live before a judging panel of senior health system executives, HIT executives and venture capitalists during the Innovation Challenge program at the HX360 inaugural event. The four finalists are: ClockwiseMD, Ginger.io, Wellframe and WiserCare.

The HX360 Innovation Challenge live pitch takes place at the 2015 HIMSS Annual Conference & Exhibition in Chicago, on Tuesday, April 14, from 2:30 to 4:30pm. Judging will be based on a number of criteria, including improved patient satisfaction, increased patient convenience and access to care, better access to health information, patient empowerment, proof of positive impact and market readiness, according to a release. Technical considerations include interoperability with existing IT systems, workflow impact, superior user interface and scalability. Two winning companies will be selected.

The four HX360 Innovation Challenge finalists have demonstrated their ability to improve patient engagement and the patient experience at hospitals and health systems. These companies are:

Clockwise.MD lets patients check in online from any web-enabled device and skip the waiting room. It keeps them informed of their expected wait time by text message, and frees them from having to sit in the waiting room. It addresses the three things patients dislike about waiting: waits of an uncertain duration, waits that are not explained and waits that are perceived as unfair.

Ginger.io brings the power of big data to behavioral health. Using machine learning analytics and passive data collected through smartphone sensors, Ginger.io identifies patterns in behavior that may impact a patient's health and well-being. That insight is then shared with patients and their care teams to help better manage health conditions and improve treatment plans.  

Wellframe is a clinically proven technology platform that converts evidence-based clinical protocols into simple, interactive, multimedia daily health checklists for patients using a mobile device. Wellframe tracks every patient's interaction with their care plan and securely shares these data in real-time with a patient's clinician via Wellframe's patent-pending, HIPAA-compliant private cloud and clinician dashboard.

WiserCare uses a patented intelligent agent to analyze the patient's clinical situation, quality of life preferences and treatment goals, and provide personalized, quantified, evidence-based guidance on what treatments fit best. This equips patients and physicians to act as decision partners in ways other tools and approaches simply can't.

The two winning companies will each be given access to $75,000 in prize money and legal services that will be used to fund new pilot programs at U.S. not-for-profit health systems using the winning teams' products and services. The winning companies will operate their pilots at healthcare systems to be identified by AVIA, the provider-led healthcare accelerator that co-founded HX360 with HIMSS.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.